Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Jun 12, 2013 11:01am

217 Views

Post# 21515244

RE: When to expect ASSURE results

Clarification. What I meant in #5 is that in the late June press release, we will likely see primary endpoint IVUS values of ASSURE (RVX treatment vs. baseline) to be shared in terms of p-values and changes in percent atheroma volume (PAV). But for secondary endpoints we might just get a summary statement or p-values but no hard data in the press release. But come the ESC meeting in August/September, we will get full disclosure of all ASSURE/SUSTAIN data. All IMO.

Bullboard Posts

The Market Online’s Weekly Cannabis Report – Nov. 15, 2024